4 November 2013Biotechnology

New frontiers: potential barriers to patenting induced totipotent stem cell technology

It has for some years been possible to create pluripotent stem cells (stem cells capable of differentiating into many, but not all, other cell types of the body) from fully differentiated adult cells (so called ‘induced pluripotent stem cells’ [iPS cells]).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

Startups toolkit: Why investors want more than patents

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Broad Institute wins appeal to restore CRISPR patent in Europe

New frontiers: potential barriers to patenting induced totipotent stem cell technology

Editor's picks

Editor's picks

More features